Veloxis Hopes Novel Slow-Release Tacrolimus Will Showcase Bioavailability Boost Of “Flat Kinetics”
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Veloxis Pharmaceuticals A/S, aka LifeCycle Pharma, is a step closer in its plan to market a slow-release version of blockbuster immunosuppressant tacrolimus that is not substitutable by the handful of generics that have become available since Astellas Pharma Inc.'s branded Prograf lost U.S. patent protection in 2009.
You may also be interested in...
Partnering Inflammation/Autoimmune Drugs Offers Sizzle And Steak
As Big Pharma companies back away from developing primary care products because of rising development costs and regulatory risk, they are increasingly turning to specialty medicines to fill their pipeline holes. One therapeutic area of particular interest: the inflammation/auto-immune space
Cowen Royalty Buyers In “Right Place, Right Time”
Deal to purchase royalty stream from LifeCycle exemplifies what deal-makers want in tight equity market.
Astellas’ Once-Daily Prograf Receives Mixed Decisions For Three Prophylaxis Claims
Company also inks monoclonal antibody deal with Kirin Brewery.